title: The effect of porous infusion balloon-delivered angiopeptin on myointimal hyperplasia after balloon injury in the rabbit.
abstract: BACKGROUND
  Angiopeptin, a synthetic somatostatin analogue, reduces myointimal hyperplasia after experimental balloon angioplasty when given subcutaneously. The feasibility and efficacy of a single dose of angiopeptin delivered locally via the Wolinsky porous balloon on myointimal hyperplasia were studied.
  
  
  RESULTS
  Three rabbits received 125I-angiopeptin in the mid abdominal aorta via the Wolinsky balloon at 5 atm for 1 minute after balloon injury. Thirty minutes later, autoradiography demonstrated radioactivity in the media and the adventitia. Forty rabbits were divided equally into one control group receiving saline and three angiopeptin groups receiving 1, 10, or 100 micrograms/mL of angiopeptin delivered locally at 5 atm for 1 minute via the Wolinsky balloon into the mid abdominal aorta after balloon injury of the entire abdominal aorta. On day 21, the abdominal aortas were fixed in situ and harvested. There was no statistical difference in the amount of myointimal hyperplasia in the locally treated aorta in the angiopeptin groups compared with the control group. However, in the lower abdominal aorta, where balloon injury without local delivery was performed, there was a significant reduction of myointimal hyperplasia in the highest-concentration angiopeptin group (P < .001 versus the control group). Electron microscopy showed that the control animals had a pseudointima of smooth muscle cells throughout the aorta, whereas in all the angiopeptin-treated animals, endothelial cells were present at both locations.
  
  
  CONCLUSIONS
  Angiopeptin can be delivered intramurally via the Wolinsky porous balloon and reduces myointimal hyperplasia only in the area distal to the local drug delivery site (downstream effect), possibly by healing the injured endothelium, by transport via the vasa vasora, and/or by systemic effect.
authors.affiliation: Department of Cardiology, Washington Hospital Center, Washington, DC 20010-2975.
authors.forename: M K
authors.initials: MK
authors.lastname: Hong
authors.forename: T
authors.initials: T
authors.lastname: Bhatti
authors.forename: B J
authors.initials: BJ
authors.lastname: Matthews
authors.forename: K S
authors.initials: KS
authors.lastname: Stark
authors.forename: S S
authors.initials: SS
authors.lastname: Cathapermal
authors.forename: M L
authors.initials: ML
authors.lastname: Foegh
authors.forename: P W
authors.initials: PW
authors.lastname: Ramwell
authors.forename: K M
authors.initials: KM
authors.lastname: Kent
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001345:Autoradiography; D001808:Blood Vessels / Q000187:drug effects* / Q000473:pathology*; D002404:Catheterization / Q000009:adverse effects*; D055598:Chemical Phenomena; D002621:Chemistry; D016503:Drug Delivery Systems; D005240:Feasibility Studies; D006965:Hyperplasia; D008297:Male; D008854:Microscopy, Electron; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000008:administration & dosage* / Q000097:blood / Q000235:genetics / Q000494:pharmacology; D010456:Peptides, Cyclic; D011817:Rabbits; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000235:genetics / Q000494:pharmacology
chemical_list: D009842:Oligopeptides; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin